Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : SCK CEN
Deal Size : Undisclosed
Deal Type : Collaboration
Navigo and SCK CEN Join Forces for Radiotheranostics R&D
Details : The two organizations aim to accelerate the development of radioligand therapies – highly specific, targeted therapies offering high efficacy with minimal side effects for cancer patients.
Product Name : Undislcosed
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
April 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : SCK CEN
Deal Size : Undisclosed
Deal Type : Collaboration